Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04477304 · ClinicalTrials.gov registry record · NA
Application of Economics & Social Psychology to Improve Opioid Prescribing Safety Trial 1: EHR Nudges
A NA study of Opioid Abuse, Unspecified, sponsored by University of Southern California.
- Completed
- Registry status
- NA
- Development phase
- 555
- Enrollment target
- 1
- Study location
NCT04477304: Completed NA study of Opioid Abuse, Unspecified, sponsored by University of Southern California.
NCT04477304 is a NA study of Opioid Abuse, Unspecified that has completed, run by University of Southern California. The registered enrollment target is 555 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04477304, a NA study of Opioid Abuse, Unspecified, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- NA
- Development phase
- 555 participants
- Enrollment target
- 1
- Study location
Study Summary
The opioid epidemic has had a tremendous negative impact on the health of persons in the U.S. The objective of the trial 1 of Application of Economics \& Social psychology to improve Opioid Prescribing Safety (AESOPS-T1), is to discourage unnecessary opioid prescribing through the application of "behavioral insights"-empirically-tested social and psychological interventions that affect choice.
Primary Outcome
Change = (18-month intervention average of natural log MME summed per-clinician, per-week - 6-month baseline average of natural log MME summed per-clinician, per-week). Log(total MME) = log(Rx strength x number of pills x opioid conversion factor)
Conditions Studied
Interventions
- BEHAVIORAL Opioid Naive, OR
- BEHAVIORAL At-risk for long-term use, OR
- BEHAVIORAL Long-term opioid recipient
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 555 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2023-08-06 |
| Phase | NA |
What the finished NCT04477304 record still lists
NCT04477304 is an interventional study that assigns participants to a tested intervention. The registered 555 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Opioid Abuse, Unspecified appearing as the primary indexed condition, and to 3 interventions - of which Opioid Naive, OR is the first listed.
NCT04477304 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04477304 about?
NCT04477304 is a clinical study titled "Application of Economics & Social Psychology to Improve Opioid Prescribing Safety Trial 1: EHR Nudges". The opioid epidemic has had a tremendous negative impact on the health of persons in the U.S. The objective of the trial 1 of Application of Economics \& Social psychology to improve Opioid Prescribing Safety (AESOPS-T1), is to discourage unnecessary opioid prescribing through the application of "be...
What is the current status of trial NCT04477304?
This trial is currently completed. It is a NA study. The enrollment target is 555 participants. The study started on 2020-12-01. Estimated completion is 2023-08-06.
What conditions does trial NCT04477304 study?
This clinical trial studies the following conditions: Opioid Abuse, Unspecified.
What interventions are being tested in trial NCT04477304?
The interventions under investigation include: Opioid Naive, OR (BEHAVIORAL), At-risk for long-term use, OR (BEHAVIORAL), Long-term opioid recipient (BEHAVIORAL).
Who is sponsoring clinical trial NCT04477304?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04477304 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04477304's enrollment target sits among peer trials
555 184th of 2000 higher than 1,817 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
- NCT06840392 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- NCT06693622 · 556 participants
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI